← back to search

Fabio Farinati

GTx (United States) · IT
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Helicobacter pylori-related gastroenterology studies, and Liver Disease and Transplantation.
h-index
73
citations
18,478
works
723
NIH funding
primary concept
Medicine
email

Recent publications

Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma
Hepatology International 2025cited by 17position: middledoi
Clinical and Endoscopic-Histological Features of Multifocal and Corpus-Restricted Atrophic Gastritis Patients With Non-Cardia Gastric Cancer or Dysplasia: A Multicenter, Cross-Sectional Study.
2025cited by 4position: contributordoi
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis.
2025cited by 3position: contributordoi
Somatic Copy Number Alterations in Circulating Cell-Free DNA as a Prognostic Biomarker for Hepatocellular Carcinoma: Insights from a Proof-of-Concept Study.
2025cited by 3position: contributordoi
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma.
2025cited by 3position: contributordoi
The current success of precision oncology relies on precision diagnostics: how quality and quantity of endoscopic biopsies impact cancer patient outcome.
2025cited by 1position: contributordoi
Differential target of oxidative damage in <i>Helicobacter pylori-</i>related and autoimmune atrophic gastritis: a single-center study.
2025cited by 0position: contributordoi
DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.
2025cited by 0position: contributordoi
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis.
2025cited by 0position: contributordoi
Distinguishing Features of Autoimmune Gastritis Depending on Previous Helicobacter pylori Infection or Positivity to Anti-Parietal Cell Antibodies: Results From the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO)
The American Journal of Gastroenterology 2024cited by 29position: middledoi
HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization
Digestive and Liver Disease 2024cited by 27position: contributordoi
Gastric cancer screening in Western countries: A call to action
Digestive and Liver Disease 2024cited by 21position: firstdoi
Distinguishing Features of Autoimmune Gastritis Depending on Previous Helicobacter pylori Infection or Positivity to Anti-Parietal Cell Antibodies: Results From the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO).
2024cited by 21position: contributordoi
Gastric cancer screening in Western countries: A call to action.
2024cited by 18position: contributordoi
Crosstalk between MicroRNAs and Oxidative Stress in Coeliac Disease.
2024cited by 7position: contributordoi
Calcitonin levels in autoimmune atrophic gastritis-related hypergastrinemia.
2024cited by 3position: contributordoi
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
The Lancet Oncology 2023cited by 181position: middledoi
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
2023cited by 131position: contributordoi
Autoimmune gastritis: long-term natural history in naïve <i>Helicobacter pylori</i>-negative patients.
2023cited by 110position: contributordoi
Duodenal <scp>alpha‐Synuclein</scp> Pathology and Enteric Gliosis in Advanced Parkinson's Disease
Movement Disorders 2023cited by 49position: middledoi
Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
2023cited by 38position: contributordoi
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies
Medicina 2023cited by 37position: middledoi
HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization
Digestive and Liver Disease 2023cited by 29position: middledoi
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.
2023cited by 28position: contributordoi
Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
Digestive and Liver Disease 2023cited by 27position: middledoi
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Sur
Digestive and Liver Disease 2023cited by 26position: middledoi
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance
Biomedicines 2023cited by 24position: middledoi
Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery.
2023cited by 23position: contributordoi
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Sur
Digestive and Liver Disease 2023cited by 20position: middledoi
Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management.
2023cited by 13position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Franco Trevisani · IRCCS Humanitas Research Hospital35 papers (2012–2023)Edoardo G. Giannini · Yale University34 papers (2012–2025)Francesco Paolo Russo · National Research Council33 papers (2017–2025)Alessandro Vitale · Presbyterian Hospital28 papers (2013–2023)Edoardo Savarino · Amsterdam University Medical Centers25 papers (2018–2025)Massimo Rugge · Fondazione Progetto Ematologia22 papers (2012–2023)Matteo Fassan · Istituto Giannina Gaslini22 papers (2019–2025)Francesco Giuseppe Foschi · University of Florence20 papers (2014–2023)Umberto Cillo · Pancreas Centre (Canada)20 papers (2012–2023) · 20 papers (2019–2025) · 18 papers (2012–2021)Filomena Morisco · Naples Community Hospital Healthcare System16 papers (2014–2023) · 16 papers (2012–2018)Alberto Zanetto · ERN GUARD-Heart15 papers (2016–2022)Rodolfo Sacco · University of Edinburgh15 papers (2014–2023)Franco Borzio · Imperial College Healthcare NHS Trust14 papers (2012–2016)Fabiana Zingone · Aziende Socio Sanitaria Territoriale Rhodense14 papers (2020–2025)Matteo Fassan · University of Padua14 papers (2012–2022)Fabio Piscaglia · Ludwig-Maximilians-Universität München13 papers (2014–2023) · 13 papers (2013–2019)